Grant Playter

The trends shaping the growth of the biologics outsourcing industry demand attention.

Shifting guidance and the growing prominence of computer software assurance exemplify the state of computer software validation.

Jill Murphy, editor, and Grant Playter, associate editor, discuss the results from Pharmaceutical Technology’s latest employment survey.

Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.

Experts weigh in on trends in the biotechnology market, psychedelics, and India.

Advances in contamination control are being to mitigate the presence of pollutants in drug products.

The state of oral solid dose manufacturing is influenced by new approaches, novel technologies, and the structural evolution of the raw materials market.

Recent technological advancements may have put cleanroom monitoring into a state of flux.

Experts outline the benefits of single-use consumables relative to traditional approaches.

Various advances in contamination control are being utilized to reduce the chance pollutants contaminate a drug product.

Cleanroom monitoring may be in a state of flux after many recent technological advancements.

In this episode, Grant Playter, assistant editor, sits down with Rosalind Beasley, vice president, Digital Innovation, Dot Compliance, to discuss the current state of the compliance and validation industry.

Dissolution testing has seen recent trends that have led to increased data integrity solutions as well as an increase in biorelevant testing techniques.

Virtual and augmented reality have emerged as critical digital training tools.

Recent trends in dissolution testing have led to increased use of data integrity solutions and more biorelevant testing techniques.

Experts weigh in on the current state of computer validation and its role in the greater regulatory landscape.

An overview of technologies aiming to improve laboratory processes from the past year.

Recent news surrounding CDMOs provides insight into ongoing trends in the sector.

Survey respondents reflect on the state and future of the bio/pharma employment.

Recent developments in the outsourcing industry include a focus on early development services, biosimilar production, and RNA technology.

While supply chain disruptions have resulted in many alterations to workplace practices, they have also presented an opportunity to get ahead of changes to the EU’s upcoming revision of Annex 1.

Laks Pernenkil, a partner for Deloitte’s life sciences consulting business, discusses various findings from Deloitte’s research into the biopharma industry.